metabolic dysfunction-associated steatohepatitis

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis

This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).